The market performance of Monopar Therapeutics Inc has been somewhat stable. Over the past year, the company’s stock achieved a high of $8.65 on 02/23/24, with the lowest value for the same timeframe being $1.37, recorded on 11/27/23.
52-week price history of MNPR Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Monopar Therapeutics Inc’s current trading price is -21.73% away from its 52-week high, while its distance from the 52-week low is 394.34%. The stock’s price range during this period has fluctuated between $1.37 and $8.65. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 1.4 million for the day, which was evidently higher than the average daily volume of 0.77 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
Monopar Therapeutics Inc (MNPR) has experienced a quarterly rise of 85.45% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 23.83M and boasts a workforce of 10 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.42, with a change in price of +2.81. Similarly, Monopar Therapeutics Inc recorded 519,747 in trading volume during the last 100 days, posting a change of +70.96%.
MNPR Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MNPR stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
MNPR Stock Stochastic Average
Monopar Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 93.87%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 93.14%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 94.06% and 84.86%, respectively.
MNPR Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price gain of 298.00% this year. Over the last six months, there has been a weaker performance of 98.83%. The price of MNPR fallen by 199.56% during the last 30 days period. For the last 5-days stocks have improved 49.12%.
